FASgen : Production and Investment Agreement with Tetracore

May 29, 2008 - FASgen Diagnostics, LLC (Baltimore) and Tetracore, Inc. (Rockville) have announced that they have entered into a collaboration to produce cGMP ELISA and IHC tests for cancer biomarkers using FASgen's proprietary antibodies. The tests measure the over-expression of the enzyme fatty acid synthase (FAS), which is found in virtually all solid tumor cancers. FASgen's FAS-detect(TM) Elisa and FAS-detect(TM) IHC tests, currently available for research purposes, have demonstrated repeated and highly significant success in identifying the progression of the disease in a series of different solid tumors, including, pancreas, ovarian, prostate and lung cancer.
These research results were recently the subject of multiple independent papers and presentations at the AACR annual meeting and at the earlier annual meeting of the Society of Gynecological Oncologists... FASgen Diagnostics' Press Release - Tetracore's Press Release -

FASgen, Significant Milestone in Its Cancer Drug Development Program

Oct. 1 , 2007 - FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available... FASgen's Press Release -